{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:41:01Z","timestamp":1770446461161,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The containment strategies during the COVID-19 pandemic between December 2019 and 2022 significantly disrupted the healthcare system. Cardiac amyloidosis has a poor prognosis and requires frequent follow-up in reference centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the impact of limited access to healthcare on the patient burden and care pathway in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This cross-sectional, self-questionnaire survey was conducted between June and October 2021 among cardiac amyloidosis patients registered at Expert Centres of the French Amyloidosis Network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 1015 patients participated of whom, 229 had light chain amyloidosis, 786 had transthyretin amyloidosis.\u00a0Disrupted clinical follow-up was reported in 21.1% of respondents, 15% had follow-up visits postponed. No alternative follow-up option was proposed for 45% of these patients. Few patients reported treatment discontinuation (Light chain (1.1%), transthyretin (1.3%). Significantly more newly diagnosed\u00a0light chain\u00a0(37.9%) than transthyretin amyloidosis patients (30.4%) reported the containment strategies caused a poor initial work-up experience (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034).\u00a0Among those patients who reported a COVID19 infection (9.7%) more patients with light chain amyloidosis (75.0%) were hospitalized than transthyretin amyloidosis (37.1%), (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Only 587 (57.0%) patients answered vaccination question, most (92.0%) reported having been vaccinated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with light chain amyloidosis reported having had a higher impact to their care management than transthyretin amyloidosis patients during the COVID19 pandemic containment periods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03859-1","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:52:46Z","timestamp":1751953966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-9831","authenticated-orcid":false,"given":"D.","family":"Guijarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jobbe-Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aguilhon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Donal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Eicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jeanneteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gellen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kenizou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lequeux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Legallois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"R\u00e9ant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salvat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Seronde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Whereat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zaroui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Damy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"3859_CR1","unstructured":"Escalon HDV, Verdot C. Physical activity and sedentary behaviour of French adults during the Covid-19 lockdown. Bull Epid\u00e9miol Hebd. 2021;2\u201313."},{"issue":"19","key":"3859_CR2","first-page":"2","volume":"7","author":"CSB Delamaire","year":"2021","unstructured":"Delamaire CSB, Ducrot P, Verdot C, Deschamps V, Serry AJ. Eating behavior and determinants of weight gain in French adults during the Covid-190 lockdown. Bull Epid\u00e9miol Hebd. 2021;7(19):2\u201311.","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"3859_CR3","unstructured":"World Health Organisation. COVID-19 has caused major disruptions and backlogs in health care, new WHO study finds 2022 [June 2023]. Available from: https:\/\/www.who.int\/europe\/news\/item\/20-07-2022-covid-19-has-caused-major-disruptions-and-backlogs-in-health-care--new-who-study-finds"},{"issue":"10248","key":"3859_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(20)31356-8","volume":"396","author":"MM Mafham","year":"2020","unstructured":"Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381\u20139.","journal-title":"Lancet"},{"key":"3859_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijcard.2020.08.094","volume":"323","author":"A Cransac-Miet","year":"2021","unstructured":"Cransac-Miet A, Zeller M, Chagu\u00e9 F, et al. Impact of COVID-19 lockdown on lifestyle adherence in stay-at-home patients with chronic coronary syndromes: towards a time bomb. Int J Cardiol. 2021;323:285\u20137.","journal-title":"Int J Cardiol"},{"issue":"6","key":"3859_CR6","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/emp2.12325","volume":"1","author":"G Rang\u00e9","year":"2020","unstructured":"Rang\u00e9 G, Hakim R, Beygui F, et al. Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: analysis from the France PCI registry. J Am College Emerg Phys Open. 2020;1(6):1168\u201376.","journal-title":"J Am College Emerg Phys Open"},{"issue":"24","key":"3859_CR7","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1056\/NEJMms2009984","volume":"382","author":"L Rosenbaum","year":"2020","unstructured":"Rosenbaum L. The untold toll\u2014the pandemic\u2019s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368\u201371.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"3859_CR8","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med. 2018;18(Suppl 2):s30\u20135.","journal-title":"Clin Med"},{"issue":"3","key":"3859_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/13506129.2022.2035354","volume":"29","author":"T Damy","year":"2022","unstructured":"Damy T, Adams D, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29(3):165\u201374.","journal-title":"Amyloid"},{"issue":"16","key":"3859_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554\u201368.","journal-title":"Eur Heart J"},{"issue":"24","key":"3859_CR11","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"2","key":"3859_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.acvd.2024.08.006","volume":"118","author":"O Lairez","year":"2025","unstructured":"Lairez O, Reant P, Inamo J, et al. Clinical outcomes for 2788 patients with transthyretin amyloidosis: tafamidis meglumine early access program in France. Arch Cardiovasc Dis. 2025;118(2):123\u201332.","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"3859_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.16898","volume":"190","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Wechalekar A, Schonland S, et al. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. Br J Haematol. 2020;190(3):346\u201357.","journal-title":"Br J Haematol"},{"issue":"4","key":"3859_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ancard.2021.07.002","volume":"70","author":"E Berthelot","year":"2021","unstructured":"Berthelot E, Flecher E, Roubille F, et al. Impact de la pandemie de COVID-19 sur la charge des patients atteints d\u2019insuffisance cardiaque chronique en France. Ann Cardiol Angeiol. 2021;70(4):191\u20135.","journal-title":"Ann Cardiol Angeiol"},{"issue":"10","key":"3859_CR15","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ejhf.1300","volume":"20","author":"F Koehler","year":"2018","unstructured":"Koehler F, Koehler K, Deckwart O, et al. Telemedical interventional management in heart failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail. 2018;20(10):1485\u201393.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"3859_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cardfail.2020.04.008","volume":"26","author":"EZ Gorodeski","year":"2020","unstructured":"Gorodeski EZ, Goyal P, Cox ZL, et al. Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the heart failure society of America. J Card Fail. 2020;26(6):448\u201356.","journal-title":"J Card Fail"},{"key":"3859_CR17","unstructured":"Lairez O. Navigating the future of transthyretin cardiac amyloidosis management: unveiling the potential of digital biomarkers for real-world cardiac progression monitoring. Heart Failure Association Congress, Lima M 2024."},{"issue":"2","key":"3859_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ehf2.13209","volume":"8","author":"R Sankaranarayanan","year":"2021","unstructured":"Sankaranarayanan R, Hartshorne-Evans N, Redmond-Lyon S, et al. The impact of COVID-19 on the management of heart failure: a United Kingdom patient questionnaire study. ESC Heart Fail. 2021;8(2):1324\u201332.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"3859_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064305","volume":"13","author":"A Perozziello","year":"2023","unstructured":"Perozziello A, Sousa D, Aubriot B, et al. Use of mental health services in the aftermath of COVID-19 waves: a retrospective study conducted in a French psychiatric and neurosciences university hospital. BMJ Open. 2023;13(2): e064305.","journal-title":"BMJ Open"},{"issue":"3","key":"3859_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/13506129.2016.1208081","volume":"23","author":"J Shu","year":"2016","unstructured":"Shu J, Lo S, Phillips M, et al. Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid. 2016;23(3):188\u201393.","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"3859_CR21","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.amjmed.2022.01.005","volume":"135","author":"ZD Crees","year":"2022","unstructured":"Crees ZD, Stockerl-Goldstein K. COVID-19 and light chain amyloidosis, adding insult to injury. Am J Med. 2022;135(Suppl 1):S49\u201352.","journal-title":"Am J Med"},{"issue":"1","key":"3859_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ajh.26762","volume":"98","author":"M Ho","year":"2023","unstructured":"Ho M, Zanwar S, Buadi FK, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98(1):49\u201355.","journal-title":"Am J Hematol"},{"issue":"6","key":"3859_CR23","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2468-2667(21)00064-5","volume":"6","author":"N Hoze","year":"2021","unstructured":"Hoze N, Paireau J, Lapidus N, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health. 2021;6(6):e408\u201315.","journal-title":"Lancet Public Health"},{"key":"3859_CR24","unstructured":"Guillaume R. COVIDTRACK VaccinTracker [cited 2023]. Available from: https:\/\/covidtracker.fr\/vaccintracker\/"},{"issue":"10","key":"3859_CR25","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00277-022-04964-y","volume":"101","author":"E Lewis","year":"2022","unstructured":"Lewis E, Fine N, Miller RJH, et al. Amyloidosis and COVID-19: experience from an amyloid program in Canada. Ann Hematol. 2022;101(10):2307\u201315.","journal-title":"Ann Hematol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03859-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:52:51Z","timestamp":1751953971000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03859-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not obtained considering the urgency of the situation and that the anonymous surveys about patient opinions that do not involve any medical procedures are tolerated under French law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TD has received grant and\/or consulting fees from: AKCEA, Alnylam, Alexion, Bridge Bio, Pfizer, Neurimmune. DL reports honoraria for presentations and consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, and Takeda, outside of the submitted work. OL has received consulting fees from Alnylam, AstraZeneca and Pfizer. DG and AJD have received consulting fees from Alnylam, Pfizer. The other authors have no funding source to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"347"}}